JP2016505556A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505556A5
JP2016505556A5 JP2015545935A JP2015545935A JP2016505556A5 JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5 JP 2015545935 A JP2015545935 A JP 2015545935A JP 2015545935 A JP2015545935 A JP 2015545935A JP 2016505556 A5 JP2016505556 A5 JP 2016505556A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015545935A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505556A (ja
JP6490591B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/074208 external-priority patent/WO2014093396A1/en
Publication of JP2016505556A publication Critical patent/JP2016505556A/ja
Publication of JP2016505556A5 publication Critical patent/JP2016505556A5/ja
Priority to JP2019034198A priority Critical patent/JP6889741B2/ja
Application granted granted Critical
Publication of JP6490591B2 publication Critical patent/JP6490591B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015545935A 2012-12-10 2013-12-10 抗血液樹状細胞抗原2抗体およびその使用 Active JP6490591B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019034198A JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261735362P 2012-12-10 2012-12-10
US61/735,362 2012-12-10
US201361763270P 2013-02-11 2013-02-11
US61/763,270 2013-02-11
PCT/US2013/074208 WO2014093396A1 (en) 2012-12-10 2013-12-10 Anti-blood dendritic cell antigen 2 antibodies and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019034198A Division JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2016505556A JP2016505556A (ja) 2016-02-25
JP2016505556A5 true JP2016505556A5 (enExample) 2017-01-26
JP6490591B2 JP6490591B2 (ja) 2019-03-27

Family

ID=49883267

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2015545935A Active JP6490591B2 (ja) 2012-12-10 2013-12-10 抗血液樹状細胞抗原2抗体およびその使用
JP2019034198A Active JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用
JP2021086053A Pending JP2021130677A (ja) 2012-12-10 2021-05-21 抗血液樹状細胞抗原2抗体およびその使用
JP2024006009A Pending JP2024045253A (ja) 2012-12-10 2024-01-18 抗血液樹状細胞抗原2抗体およびその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2019034198A Active JP6889741B2 (ja) 2012-12-10 2019-02-27 抗血液樹状細胞抗原2抗体およびその使用
JP2021086053A Pending JP2021130677A (ja) 2012-12-10 2021-05-21 抗血液樹状細胞抗原2抗体およびその使用
JP2024006009A Pending JP2024045253A (ja) 2012-12-10 2024-01-18 抗血液樹状細胞抗原2抗体およびその使用

Country Status (25)

Country Link
US (3) US9902775B2 (enExample)
EP (2) EP2928923B1 (enExample)
JP (4) JP6490591B2 (enExample)
KR (2) KR20150094658A (enExample)
CN (2) CN105452295B (enExample)
AU (1) AU2013359419B2 (enExample)
BR (1) BR122020023058B1 (enExample)
CA (1) CA2893375A1 (enExample)
CY (1) CY1122956T1 (enExample)
DK (1) DK2928923T3 (enExample)
EA (1) EA034757B1 (enExample)
ES (1) ES2780398T3 (enExample)
HR (1) HRP20200174T1 (enExample)
HU (1) HUE047874T2 (enExample)
IL (2) IL238804B (enExample)
LT (1) LT2928923T (enExample)
MX (1) MX363407B (enExample)
NZ (1) NZ708033A (enExample)
PL (1) PL2928923T3 (enExample)
PT (1) PT2928923T (enExample)
RS (1) RS60084B1 (enExample)
SI (1) SI2928923T1 (enExample)
SM (1) SMT202000193T1 (enExample)
WO (1) WO2014093396A1 (enExample)
ZA (1) ZA201503881B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2968561B1 (fr) † 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire
WO2015095143A1 (en) 2013-12-16 2015-06-25 The University Of North Carolina At Chapel Hill Depletion of plasmacytoid dendritic cells
CN109535254B (zh) * 2013-12-24 2022-06-24 安斯泰来制药株式会社 抗人bdca-2抗体、其生产方法、多核苷酸、表达载体、宿主细胞及医药组合物
FR3034420A1 (fr) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement Anticorps monoclonaux anti-cd303
FR3045386B1 (fr) 2015-12-16 2018-02-02 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation d'un anticorps dirige contre une proteine membranaire
EP3448425A1 (en) * 2016-04-28 2019-03-06 Biogen MA Inc. Pharmaceutical compositions and dosage regimens for clinical use of anti-blood dendritic cell antigen 2 antibodies
CN110283803B (zh) * 2016-06-02 2021-08-03 天津科技大学 一种磷脂酶d及其制备磷脂酸、磷脂酰丝氨酸的方法
CN110709417B (zh) * 2017-04-07 2023-10-31 美天施生物科技有限责任两合公司 具有突变人IgG4的多肽
EP3785029A1 (en) * 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
CN112867394B9 (zh) * 2018-06-04 2024-12-06 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
EP3890773A4 (en) * 2018-11-08 2022-11-09 Orionis Biosciences, Inc. MODULATION OF DENDRITIC CELL LINES
JP7753188B2 (ja) * 2019-08-05 2025-10-14 センテッサ ファーマシューティカルズ (ユーケー) リミテッド 抗bdca-2抗体
CN116963716A (zh) * 2020-12-03 2023-10-27 渤健马萨诸塞州股份有限公司 治疗皮肤型红斑狼疮和系统性红斑狼疮的方法
WO2022129120A1 (en) * 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
CN113484512B (zh) * 2021-06-01 2023-06-27 中国农业科学院油料作物研究所 黄曲霉毒素风险预警智能感知卡及其应用
TW202400652A (zh) * 2022-05-25 2024-01-01 大陸商映恩生物製藥(蘇州)有限公司 抗bdca2抗體及其用途
WO2024010118A1 (ko) * 2022-07-07 2024-01-11 주식회사 유틸렉스 항 bdca-2 항체 및 이의 용도
WO2024031082A2 (en) * 2022-08-04 2024-02-08 New Paradigm Biosciences Usa, Inc. Depletion and inhibition of plasmacytoid dendritic cells
WO2024140838A1 (zh) * 2022-12-28 2024-07-04 映恩生物制药(苏州)有限公司 抗bdca2抗体-药物偶联物及其用途
CN121194991A (zh) * 2023-05-10 2025-12-23 英脉生物医药(杭州)有限公司 Bdca2靶向抗体及其用途
CN119119267A (zh) 2023-06-12 2024-12-13 三生国健药业(上海)股份有限公司 抗bdca2抗体
WO2025051083A1 (zh) 2023-09-05 2025-03-13 上海宏成药业有限公司 抗bdca-2特异性抗体及其用途
WO2025091023A1 (en) * 2023-10-27 2025-05-01 Northwestern University Engineered cell transfected by all-in-one vector for therapeutic agents production and delivery and applications thereof
CN122080215A (zh) * 2023-12-05 2026-05-26 苏州普乐康医药科技有限公司 一种抗bdca-2抗体及其应用和产品
CN118667008A (zh) * 2024-05-24 2024-09-20 深圳科兴药业有限公司 靶向bdca2的抗体或其抗原结合片段及其应用
WO2026008012A1 (zh) * 2024-07-04 2026-01-08 杭州博之锐生物制药有限公司 抗bdca2抗体及其用途
CN118638234B (zh) * 2024-07-04 2025-10-14 杭州博之锐生物制药有限公司 抗bdca2抗体及其制备方法和应用
CN119591712B (zh) * 2024-11-27 2025-11-21 纽迈生物科技(苏州)有限公司 靶向人类浆细胞样树突状细胞的单克隆抗体及其应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
DE68927933T2 (de) 1988-09-02 1997-08-14 Dyax Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
SE9201984D0 (sv) 1992-06-29 1992-06-29 Pharmacia Biosensor Ab Improvement in optical assays
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6201671B1 (en) 1998-12-04 2001-03-13 International Business Machines Corporation Seed layer for a nickel oxide pinning layer for increasing the magnetoresistance of a spin valve sensor
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US7030228B1 (en) * 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
JP5007007B2 (ja) * 1999-11-15 2012-08-22 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞
US20070148171A1 (en) 2002-09-27 2007-06-28 Xencor, Inc. Optimized anti-CD30 antibodies
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003254019A1 (en) * 2002-07-18 2004-02-09 Dana-Farber Cancer Institute, Inc. Compositions and methods to select dendritic cells from a heterogeneous cell population
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7355008B2 (en) 2003-01-09 2008-04-08 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004205631A1 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
PL378110A1 (pl) 2003-02-14 2006-03-06 Biogen Idec Ma Inc. Kaseta ekspresyjna i wektor do przejściowej albo stabilnej ekspresji egzogennych cząsteczek
DK1639014T3 (da) 2003-06-13 2011-01-17 Biogen Idec Inc Aglycosyl-anti-CD154 (CD40-ligand)-antistoffer og anvendelser deraf
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
US20060134105A1 (en) 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
JP2008500271A (ja) * 2003-10-14 2008-01-10 ザ・プロウボウスト・フェロウズ・アンド・スカラーズ・オブ・ザ・カレッジ・オブ・ザ・ホリー・アンド・アンデバイデッド・トリニティ・オブ・クイーン・エリザベス・ニア・ダブリン 免疫介在性疾患の治療および/または予防におけるアデニル酸シクラーゼ
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
WO2005063815A2 (en) 2003-11-12 2005-07-14 Biogen Idec Ma Inc. Fcϝ receptor-binding polypeptide variants and methods related thereto
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB-特异性抗体及其使用方法
CA2566473A1 (en) * 2004-05-17 2005-12-08 Board Of Trustees Of The University Of Illinois Uses of bispecific antibody (biab) coated dendritic cells pulsed with antigens
BRPI0514068B8 (pt) 2004-08-04 2021-05-25 Applied Molecular Evolution Inc anticorpo anti-cd20, e, composição farmacêutica
DK2573114T3 (en) 2005-08-10 2016-07-04 Macrogenics Inc The identification and production of antibodies with variant Fc regions, and methods of using same
US8282964B2 (en) * 2007-10-27 2012-10-09 Medical Diagnostic Laboratories, Llc Ex-vivo treatment of peripheral plasmacytoid dendritic cells with IFN-lambda
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
JP2012507555A (ja) * 2008-10-31 2012-03-29 アボット バイオセラピューティクス コーポレイション 稀少疾患の治療における抗cs1抗体の使用
AR075989A1 (es) 2009-04-10 2011-05-11 Lilly Co Eli Anticuerpo dkk -1 (dickkopf-1) humano disenado por ingenieria
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗cdcp1抗體
FR2968561B1 (fr) * 2010-12-13 2013-08-09 Lfb Biotechnologies Utilisation d'un anticorps dirige contre une proteine membranaire

Similar Documents

Publication Publication Date Title
EP3668898B1 (en) Humanized antibodies for cd3
US11352432B2 (en) Antibodies specifically binding to human IL-1R7
CN111484555B (zh) 新型双特异性cd3/cd20多肽复合物
JP2021524244A5 (enExample)
JP2015533853A5 (enExample)
JP2018519364A5 (enExample)
RU2013125457A (ru) Комбинация антител против с-мет
HRP20201375T1 (hr) ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE
CN110536903A (zh) 抗ox40抗体及其用途
JP2013545738A5 (enExample)
JP2022517441A (ja) Btla抗体
JP2018503380A5 (enExample)
RU2010149746A (ru) Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
JP2022507485A5 (enExample)
JP2020523038A5 (enExample)
JP2013519690A5 (enExample)
EP4146698A1 (en) Sirp alpha, sirp beta 1, and sirp gamma antibodies and uses thereof
JP2021533796A5 (enExample)
JP2015509960A5 (enExample)
JP2025041695A (ja) 抗体および使用方法
JP7698635B2 (ja) 抗幹細胞因子抗体及びその使用方法
CN116234826A (zh) Btla抗体
JP2018529672A5 (enExample)
EP4392063A1 (en) Antibodies targeting immunosuppressive b cells
AU2022332971A1 (en) Methods of treating cancers associated with immunosuppressive b cells